|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1018 |
Guru Rank Value : 0.1 |
Guru Occurances : 4 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
714 |
160,302 |
276,407 |
571,147 |
Total Sell Value |
$64,260 |
$13,335,112 |
$23,824,420 |
$53,365,721 |
Total People Sold |
1 |
5 |
6 |
7 |
Total Sell Transactions |
1 |
11 |
22 |
49 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Davis George Eric |
VP, General Counsel |
|
2007-02-22 |
4 |
OE |
$6.13 |
$79,690 |
D/D |
13,000 |
13,000 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2007-02-22 |
4 |
AS |
$18.40 |
$18,400 |
D/D |
(1,000) |
19,642 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2007-02-20 |
4 |
AS |
$16.96 |
$220,481 |
D/D |
(13,000) |
20,642 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Ops |
|
2007-02-14 |
4 |
AS |
$20.00 |
$300,000 |
D/D |
(15,000) |
2,829 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Ops |
|
2007-02-14 |
4 |
OE |
$7.16 |
$107,400 |
D/D |
15,000 |
17,829 |
|
- |
|
Swiedler Stuart J |
SVP, Clinical Affairs |
|
2007-01-03 |
4 |
AS |
$16.30 |
$203,700 |
D/D |
(12,500) |
10,000 |
|
- |
|
Swiedler Stuart J |
SVP, Clinical Affairs |
|
2007-01-03 |
4 |
OE |
$4.00 |
$50,000 |
D/D |
12,500 |
22,500 |
|
- |
|
Lapalme Pierre |
Director |
|
2006-12-12 |
4/A |
B |
$17.88 |
$17,880 |
D/D |
1,000 |
5,500 |
2.39 |
- |
|
Lapalme Pierre |
Director |
|
2006-12-12 |
4/A |
B |
$17.89 |
$19,676 |
I/I |
1,100 |
1,100 |
2.1 |
- |
|
Lapalme Pierre |
Director |
|
2006-12-12 |
4 |
B |
$17.88 |
$37,556 |
D/D |
2,100 |
6,600 |
2.39 |
- |
|
Cooper Jeffrey H |
Chief Financial Officer |
|
2006-12-06 |
4 |
AS |
$18.00 |
$261,000 |
D/D |
(14,500) |
0 |
|
- |
|
Cooper Jeffrey H |
Chief Financial Officer |
|
2006-12-06 |
4 |
OE |
$8.10 |
$117,450 |
D/D |
14,500 |
14,500 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Ops |
|
2006-11-29 |
4 |
S |
$17.23 |
$86,150 |
D/D |
(5,000) |
2,829 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Ops |
|
2006-11-29 |
4 |
OE |
$7.16 |
$35,800 |
D/D |
5,000 |
7,829 |
|
- |
|
Swiedler Stuart J |
SVP, Clinical Affairs |
|
2006-11-01 |
4 |
AS |
$15.92 |
$198,975 |
D/D |
(12,500) |
10,000 |
|
- |
|
Swiedler Stuart J |
SVP, Clinical Affairs |
|
2006-11-01 |
4 |
OE |
$4.00 |
$50,000 |
D/D |
12,500 |
22,500 |
|
- |
|
Kakkis Emil D |
Chief Medical Officer |
|
2006-10-31 |
4 |
B |
$3.43 |
$15,000 |
D/D |
4,368 |
38,144 |
2.74 |
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2006-10-31 |
4 |
B |
$6.92 |
$19,103 |
D/D |
2,761 |
33,642 |
2.81 |
- |
|
Baffi Robert |
SVP, Technical Operations |
|
2006-10-31 |
4 |
B |
$3.43 |
$13,372 |
D/D |
3,894 |
30,440 |
2.74 |
- |
|
Aselage Steve |
SVP, Global Commercial Ops |
|
2006-10-31 |
4 |
B |
$6.92 |
$12,939 |
D/D |
1,870 |
2,829 |
2.74 |
- |
|
Cooper Jeffrey H |
VP, Chief Financial Officer |
|
2006-08-29 |
4 |
AS |
$16.00 |
$416,000 |
D/D |
(26,000) |
0 |
|
- |
|
Cooper Jeffrey H |
VP, Chief Financial Officer |
|
2006-08-29 |
4 |
OE |
$6.13 |
$198,780 |
D/D |
26,000 |
26,000 |
|
- |
|
Klein Joseph III |
Director |
|
2006-08-09 |
4 |
S |
$15.52 |
$310,320 |
D/D |
(20,000) |
10,000 |
|
- |
|
Klein Joseph III |
Director |
|
2006-08-09 |
4 |
OE |
$7.72 |
$231,600 |
D/D |
30,000 |
30,000 |
|
- |
|
Lapalme Pierre |
Director |
|
2006-08-07 |
4 |
B |
$15.35 |
$15,350 |
D/D |
1,000 |
4,500 |
2.39 |
- |
|
1303 Records found
|
|
Page 50 of 53 |
|
|